Risk and outcomes of COVID-19 in patients with multiple sclerosis
Calls for Coordinated Action on Brain Health in European Parliament on Brain Health Day
March 18, 2026
The European Parliament marked Brain Health Day: Prevention, Policy, Progress with a high‑level programme hosted by MEP Angelika Winzig, bringing renewed political attention to Europe’s urgent need for an integrated brain health strategy.
EAN 2026 Hits New All-Time Abstract Submission Record
February 13, 2026
Join us for Brain Health Day: Prevention, Policy, Progress
February 11, 2026
Latest Posts
-
-
Breaking newsCOVID-19
Predictive factors of smell recovery in a clinical series of 288 COVID-19 patients with olfactory dysfunction
July 1, 2021Predictive factors of smell recovery in a clinical series of 288 COVID-19 patients with olfactory dysfunction -
Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine
-
Breaking newsCOVID-19
Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination
July 1, 2021Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination -
Skeletal Muscle and Peripheral Nerve Histopathology in COVID-19
-
Breaking newsCOVID-19
Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation
July 1, 2021Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation -
Breaking newsCOVID-19
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
July 1, 2021Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans -
Breaking newsCOVID-19
Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species
July 1, 2021Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species -
Breaking newsCOVID-19
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
July 1, 2021BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants -
Breaking newsCOVID-19
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
July 1, 2021Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals -
Breaking newsCOVID-19
Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection
July 1, 2021Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection -
Breaking newsCOVID-19
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
July 1, 2021Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection -
Breaking newsCOVID-19
The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis
July 1, 2021The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis -
Breaking newsCOVID-19
Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis
July 1, 2021Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis -
Breaking newsCOVID-19
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
July 1, 2021Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum









